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Resection of the lIver for colorectal carcinoma 
metastases: A multi-institutional study of 
indications for resection 
Registry of Hepali( Mt"taslases· 
In an Inuesliga/lon of the indIcatIOns for hepatIc resectIOn In thc trealment of colorectat 
carcinoma melastases. thc records of 859 pallents who had undergone thIS procedure 
were revIewed ThIS pallfnl group. from 24 InstllutlOns, was found to haue a 5-year 
acluana! run'wal of 33% and a 5-yfQ T actuarial dIsease-free sunllllal oj 27%. The only 
jactors that might by themse/;'es be considered contraindlcatlOns to hepallc resection are 
the presence of posltll" hepatIc nodes, Ihc pusence oj resectabh extrahepallc 
melastases, or thc preSfna of jour or mOrt metastases. Other fac/on that had a 
nega/lve effect on long-term sun'lua! were margIns of reJ('ctlOn on the /zl'er me/as/ases 
less than or equal to 7 em (S (5-year actuanal sUTl'll'al) = 23%). the presence of 
pOSItIVe mesente[lc nodes In the pnmary tumor specImen (S = 23%), and a 
disease-free interl'al of less than 7 year (S = 24%). The effect of anyone of these 
factors was not greal enough to contraIndIcate resection. Howetler, combinatIons of 
prognostIC faclors must be ((Ins/dered before resec/wn IS recommended. The overall 
5-year sun'Il'ai rate for thiS large senes has been very salislYlng. DecIsIon making In 
the future must take Into account such factors as number of metastases, extrahepatic 
Involvement, and stage of the pnmary tumor. 
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err~qgE Rf.'ICTIt" I' th~ onh curativ(" tr~atm~nt cur-
r~ntly available for rolor~rtal carcinoma m!"ta~tasr~ to 
th~ fiv~rI and it is estimat~d that ever) y~ar approxi-' 
mat~ly 6,000 to 12,000 patients in thr enited Statrs are 
candidates for this proc!"dure ' : mrniou~ studi!"s sug-
g!"st that th!" 5-nar sUT'\'ival from this procedurr is in 
the rangr of 25')0 to 35')' •. '" HowrvCf, at this time, only 
an estimated 1,000 hepatic resections are done each 
yrar in the l'nited Statrs (personal communication). 
The limited use of this procedure stems from three 
common beliefs: (1) Hrpalic mrtastases are fatal 
regardless of treatmrnt, (2) hepatic resection is effective 
only for solitary metastases, and (3) hepatic resection 
results in extreme morbidity and a high mortality rate. 
The third belief can be readily dismissed, as the 
mortality rate for hepatic resection has been addressed 
in several previous articles and is only about 5%. '-<, 
This is a rate considered acceptable for a major surgical 
procedure, The purpose of this article is to evaluate the 
first two beliefs. 
A collaborative effort involving 24 institutions inti-
mately involved in hepatic resection provided data on a 
large series of patients in order to answer questions 
regarding the indications and contraindications to 
hepatic resection, Our results indicate that 5-year 
survival of patients is not unusual after hepatic resec-
tion and that multiple metastases, bilobar metastases, 
or large metastases are nOl, in themselves, contraindi-
cations to this procedure. 
METHODS 
Patient population. Eight hundred fifty-nine 
patients who had undergone curative hepatic resection 
for treatment of coloreetal carcinoma metastases 
between 1948 and 1985 made up the study population 
Patients who died postoperatively (within 30 days of 
operation) and patients who had gross tumor left in situ 
have been excluded. Consecutwe patients from each of 
24 recording institutions were reviewed and entered 
into a central data base Two institutions recorded 
more than 100 patients, 3 institutions recorded 50 to 
100 patients, 6 institutions recorded 20 to 50 patients, 
and 13 institutions recorded fewer than 20 patients. 
Confidentiality prevents our stating the exact number 
of patients from each hospital. However, we can 
confirm that each institution recorded all consecutive 
hepatic resections performed in the study period by 
participating surgeons. Chart review was governed by 
a standard data retrieval protocoL Investigators at each 
institution were asked to review their patient charts to 
complete the data form. The senior author (K. S. H.) 
visited the institutions where this was not feasible to 
direct" r('\ 1('\\ thr p;1tirnt (harts ThiS re~ultEDd In 
approximate" two third, of the charts heIn\?, re\ln, ('d 
bva single author qhi~ samc author also re\lr\\ed all 
data sheet~ beforc their entn Into the computrr In an 
cffort to makr this a uniform interpretation of retro· 
spective data. 
Data forms. A standard data form yya~ de~ll?InEDd to 
retri('ve information on se\'eral aspects of the priman 
colorectal tumor, such as the date of primary resection. 
the location of the primary tumor, and the presen( e (If 
absence of metastases to local lymph nodes. The form 
also recorded information on the status of the patient 
before undergoing hepatic resertion, such as the date of 
diagnosis of the liver metastases. the carcinoembryonic 
antigen (CEA) assay before reseC'tion, and th(' presence 
of symptoms or signs of hepatic metastases (for exam-
ple. nausea, abdominal fullness. abdominal mass. jaun-
dict', and palpable ht'patomegaly). Signs and symptoms 
of liver metastases were considered only in patients 
with liver metastases in situ more than 2 months after 
colon resection. to avoid confusion with symptoms of 
the primary tumor In addition, information was 
recorded about the hepatic resection procedure, such as 
the date and type of resection, the presence or absence 
of extrahepatic disease, the presence of portal or celiac 
lymph nodes, the presence of contiguous spread (direct 
invasion or adhesion to adjacent structures). or the 
presence of discontiguous metastases (that is, simulta-
neous metastases outside the liver to the lungs, perito-
neum, small bowell, etc.). The synchronous presence of 
the primary colon tumor was not considered a discon-
:inuous metastasis, but an anastomotic recurrence after 
removal of a primary colon carcinoma was considered 
to be discontinuous extrahepatic disease Data 
retrieved from the pathologic specimen included the 
number of metastases, the distance to the closest 
margin, and the largest diameter of each metastasis. 
Follow-up data recorded included the date of the most 
recent follow-up. the status of the patient (alive with 
disease., alive without dis('ase. dead without disease. 
dead with disease). thc sitc of initial recurrencc after 
hepatic resection, and all other sites of recurrence after 
the initial site of recurrence. 
Statistical analysis, The data base was maintained 
under thc DBASE III data base management system 
on a microcomputer and uploaded to a main frame for 
analysis. The distribution of survival and disease-free 
survival was estimated with the standard Kaplan-
Meier method, Disease-free survival was defined as 
time until death or recurrence, whichever occurred 
first. For patients who died of disease, if the date of 
recurrence was unknown the date of death was used for 
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the calculation of disease·free survival. Distributions of 
survival or disease-free sur-'ival were compared bv 
means of the log rank test. If more than two groups 
were involved (such as free interval of less than 2 
months, 2 to 12 months, more than 12 months) 
pain"'ise comparisons were made only if the overall test 
statistic was significant at the 0.05 level. In some cases 
results for merged groups were reported but the 
original significance tesl was based on group bound-
aries defined independently of the results The mul-
tivariate analyses were based on the proportional 
hazards model of Cox'"' Five-year sur-'ival and disease· 
free survival rates were estimated from the Kaplan-
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Meier curves and multivariate analyses. The cur-es 
themselves appeared to plateau around 5 years for S{'ts 
with sufficient numbers of patients. In many cases the 
5-year {'stimates are associated with wide confidence 
inter-'als, and this imprecision is mentioned. In some 
cases the estimation is so imprecise that estimates are 
not reported Even for a data set as large as this. there 
are many comparisons of interest that can be made onh 
with inadequate statistical power (for example, com-
parison of outcomes for stage C patients with two 
versus three metastases). \\'e try to indicate when 
"negative" results are not conclusive because of inade-
quate statistical power. 
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Eight hundred fift\ -nim patifnt~ wrrr studied 
Thrre hundred ninety-one ha'r died Thr patirnts stili 
ali'f havr a median f01low-up timr of 21 months. and 
O"~o of them have been f0110wed up for at least 40 
months The 5-yrar anuarial survival (S) for thiS 
group of 859 patients was PP~oK with a ,-yrar actuarial 
disease-frel" survival (DFS) of 21"lo (Fig 1) Sub-
groups of patil"nts werl" studil"d to evaluate thr eflens of 
various factors on prognosis. The patients were divided 
into three groups (1) patients with metastases to the 
common duct or celiac nodes at the timr of resrction; 
(2) patients with extrahepatic, disrontiguous mrtastatic 
disease at thr time of resenion; and (3) patients with 
resection of isolated hepatic metastasrs All patients in 
all groups had undergone surgical remO\al of all gross 
disease. 
Group 1. Common duct or celiac node involve-
ment 
The presence of metastases in the common duct or 
celiac nodes appears to be a significant determinant of 
survival after hepatic resection. Of the 24 patil"nts with 
positive nodes, 17 had died and nonl" have Jived 5 years. 
Their survival distribution is significantly worse than 
that of patients without positive nodes (p < 0.0001). 
Group 2. Lxtrahepatic discontiguous disease 
This group does not include patients with a synchro-
nous primary colorectal cancer in situ. Patients with 
extrahepatic discontiguous disease (other than common 
duct or celiac nodes) had a shorter disease-free survival 
than patients without such involvement (p < 0.01), but 
the survival distributions did not appear 10 differ. As 
data included only 37 patients with discontiguous 
involvement, we cannot conclude that survival is nOI 
impaired. The follow-up for this group of patients is 
also not sufficient 10 enable us to estimate ,-year 
survival or disease-free survival rates with reliability. 
To date, however, we have had no 5-year disease-free 
survivors among these patients. 
Group 3. Curative removal of isolated hepatic 
metastases 
The 798 patients who had curative remO\'al of 
isolated hepatic metastases had as-year aClUarial 
survival of 33% and a S-year actuarial disease-free 
survival of OO~oK Analysis of individual prognostic 
indicators for this group (Table I) revealed the follow-
109 
.\.1aTgl1l of resectIOn. Information on margin of 
resection was available for only a limited number of 
patients, but this factor appeared to ~ significant. 
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Fig. 1. Survival (-) and di,('Jse-free sun·i\al 
(. - - -) for 8:'9 mg:fEDnt~ who ha\e undergone hrpati( 
re,ectlon for wlor('rtal carcinoma mEDta~taIE" to the liver. 
Patients with a margin that was greater than 1 cm 
(n = 107, S = 4T~oI DFS = 33"lo) had a significantly 
improved survival and disease-free survival when rom-
pared with patients with a pathologic margin of 1 cm 
or less (n = 203, S = 23u,"o, DFS = 13%) (p = 
< 0.01). 
Stage of the pnmaT) tumor Patients with a stage B 
primary colorectal carcinoma (n = 226, S = 47 %, 
DFS = 28%) had a significantly improved survival and 
disease-free survival when compared with patients 
with a stage C primary colorectal carcinoma (n - 317, 
S = 23%, DFS = 18"lo) (p = < 0.001). 
,\'umber of metastases. Patients with a solitary 
metastasis (n = S09, S = 37"lo, DFS = 2Su,"o) had a 
survival and disease-free survival similar to that of 
patients with two metastases (;\" = 131, S = 37 "lo , 
DFS = 25%). Both of these groups seem to have an 
improved survival over patients with three metastases, 
patients with four or more metastases, and patients 
with multiple metastases (number of metastases not 
recorded). The numbers of patients with exactly three 
or four metastases are not sufficient for S-year survival 
and disease-free survival rates to be reliably estimated 
separately for each group. For the combined group of 
149 patients with three or more metastases, the actuar-
ial 5-year survival was 18% and the 5-year disease-free 
survival was 7%. £\'en these figures are unstable, since 
only four of the 149 patients are alive after 5 years. 
Although it is difficult to draw adequate groupings 
with regard to number of metastases, patients with 
exactly there metastases have significantly poorer dis-
ease-free survival than those with a single metastasis 
, 
I 
t 
I.p < 001) or two mrta~taseR IJ> < (101) Patients with 
four or mor~ metastases appor w d{l at Ir.]q as 
poorly 
DI'itlhlJllnn of mrtol/a\(\ Patirnts with muftirlr. 
unilobar mrtastase" did not ha\e a si~nifyEanth 
impro\('d survival (1' > 020) or dlSclsc-frcr suni\'al 
I.p > 0.40) whrn (omparcd with patients with multi-
ple. bilobar metasta"e, There were onl\ -, patients 
with bilobar disease. and their follow-up is not ade-
quat~ to enable us to reliably estimate a ,-,ear survival 
or disease-free suni\al for them (onl\' two such 
patients are alive with more than 5 years' follow-up). 
Although we find no evidence that distribution is an 
important prognostic factor for patients with multiple 
metastases, definitive ronclusions require longer fol-
low-up of these patients, 
S!ZC of solzlary mflasla.lt'5. Patients with a solitary 
metastasis that was less than or equal to 2 em (n = 113. 
S = PR~MI DFS = 24'70), patients with a solitary metas-
tasis 2 to 4 em in diameter (n = 130. S = 37%. 
DFS = 27%), and patients with a solitary metastasis 
that was 4 to 8 em in diameter (n = 143. S = 43%, 
DFS = 27'70) appeared to have similar survival and 
disease-free survival. Patients with a solitary metastasis 
greater than or equal to 8 em (n = lOl, S = 27%, 
DFS = 21'70) appeared to have a somewhat decreased 
5-year survival and disease-free sunival. though these 
differences were not statistically significant. Similar 
differences appeared to exist for patients with two 
metastases. 
Symptoms oj izl'er metastases. Patients with symp-
toms of metachronous metastases (n = 93, S = 32'70 ) 
appeared to have a small but statistically significant 
reduction in sun'\\'al when compared with patients 
without symptoms ('1 :: 226. S = 45'7,) (p = O.OS) 
CEA tel'el before tWCT resectIOn. Data on CEA level 
were available for a minority of patients. Patients with 
a CEA of nglml or less (n = 45. S = 47%, 
DFS = 42%) appeared to have an improved survival 
(p = 008) and disease-free survival (p = 0 15) when 
compared with patient> with a CEA of 4 to 30 ngml 
(n = 126, S = :: 30%, DFS = 19~~F or patients with a 
CEA greater than 30 ng'ml ('1 = 145, S = 28%, 
DFS = 14%) Larger numbers and longer follow-up of 
patients in the group with a CEA of less than 4 ng ml 
are necessary to substantiate this trend. 
ContIguous Invo/t'ement of adJacent structures. 
Patients with contiguous spread of disease appear to 
have somewhat reduced disease-free survival compared 
with patients without contiguous spread (p = 007), 
The extent of follow-up for patients with contiguous 
spread is inadequate to estimate 5-year disease-free 
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suni\'al rate~ (Onh fpur of 104 ~uE h patient, arr alne 
with(>ut returren!e With :, year~ follow-up \ 
[)l\ca\/··{r(, lroi,'r: at. Patirnts with a disr.lsr-frer 
intfT\'al grrater than 1 year ('1 = 3}}, S = 42"', 
DFS = 26(7,'0) had a signifHanth Impru\cd SUr\!\d! 
(p < 0.01) and discd~ED-free survival V, < 0(2) when 
(Ompared with patimt~ with a disease-free intenJI b, 
than or equal to 1 year ('1 = 214. S = 240-0 . 
DFS:: 16<'io) Patients with disease-free inteT\als less 
than 1 month had survival rates to similar to those with 
intervals of 2 to 12 months. 
Agc a/ l!i'er resectIOn. There were 74 patients 
younger than 40 years old and 88 patients older than 
70 years Although there was some suggestion that the 
older group had somewhat shorter survivals than those 
younger than 70. this difference did not approach 
statistical signiflcance on this uni\ariate anahsis 
SurgIcal prulfdurc JOT a soh/a r) m<'laJtas!S. Patients 
who underwent a major anatomic resection ('1 = 26'7. 
S = 41 ~oI DFS = 29%) did not have a signiflcantly 
improved survi\'al or disease-free survival when com-
pared with patients who underwent a wedge resection 
of a solitary metastasis ('1:: 235, S = 35%. 
DFS = 210/0). However, when patients were consid-
ered by size of the solitary metastases and type of 
resection, a difference was suggested The 54 patients 
who underwent a wedge resection for a solitary lesion 
greater than 4 cm in diameter had a decreased survival 
and disease-free sun iva) when compared with the 177 
patients who underwent an anatomic resection for a 
solitary lesion greater than 4 cm (p < 0.02), Patients 
with lesions less than 4 cm appeared to have similar 
survivals and disease-free survivals. regardless of 
whether a wedge or an anatomic resection was per-
formed Of patients with solitary lesions greater than 4 
em, those who underwent anatomic resection had more 
favorable prognoses with regard to Dukes' stage (51% 
C) and disease-free inten'al (37% synchronous) than 
did those who underwent wedge resections (69% C and 
57% synchronous). We compared the procedures with 
Cox's proponional hazard regressIOn model to adjust 
for stage and disease-free inten'al. The effect of surgi-
ca.l procedure appeared to persist as statistically signif-
icant, even after adjustment. The limited sample size 
for the number of factors included, however, renders 
the result less than conclusive. 
The two subsets determined by size greater than or 
less than 4 cm for patients with solitary metastases 
were the only subsets for which procedures were 
compared. Hence this finding is not the result of 
excessive data manipulation. Nevertheless, the compar-
ison is not based on random allocation of treatments 
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and the groups may be prognostically differ("nt in ways 
we could not detect or appropriateh' adjust for. 
,\luI/Il'anale analyszs Multivariate analysis of the 
joint effects of the above factors on survival and 
dis~ase-free survi\al was performed for patients with-
out extrahepatic nodal or disrontiguous imoh'ement. 
Single-variabk analyses, such as described above, are 
sometimes miskading because of the confounding 
effects of other variables, The multivariate analysis 
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indicated that (I) stage of tht' primary tumor, (2) 
number of metastases, (3) presence of a metastasis 
greater than 8 em in size. (4) disease-free interval 
before hepatic resection, and (5) age older than 70 were 
independent prognostic determinants of survival. All of 
these factors, except for age. were highly significant 
I.p < 0.01) in the multi\'ariate analysis. Age was of 
borderline significance I.p < 0.05). The analysis indi-
cated that there is a gradation of risk associated with an 
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increasing number of metastases: one. two. three, and 
greater than or equal to four. The analysis also 
indicated that the less favorable prognosis associated 
with the presence of a metastasis of at \east 8 cm was not 
limited to solitary metastases, this probably was also the 
case for patients with two metastases. Large size does 
appear to have a detrimental effect, but even this set of 
data is inadequate. with the current limited degree of 
follow-up, to determine the exact nature of this inter-
action between size and number of metastases. 
The predictions based on the multivariate model 
indicate that patients with stage C disease and three or 
more metastases do extremely poorly. In our data there 
are no patients with stage C disease and three or more 
metastases who have survived 5 years. The model 
predicts that the 5-year survival rate for stage C 
patients with three or more mt'tastases is less than 100/0, 
even if the disease is metachronous. For patients with 
synchronous stagt' C disease, who art' either older than 
70 or have a lesion greater thar, 8 em, the predicted 
5-year survival rate is less than 151fo, regardless of the 
number of metastases. Patients with stage B disease 
and fewer than four metastases are predicted to have 
relatively good ,-year survi\'al probabilities These 
probabilities are reduced substantially for those with 
large metastases or for those older than 70 and are 
increased for those with metachronous disease. The 
predicted probabilities of 5-year survival and disease-
free survival are limited in precision bera '.lse of the 
limitation of follow-up of these patients. 
DISCUSSION 
Approximately 40,000 persons with colorenal carci-
noma die of hepatic metastases each year. The only 
curative treatment currently available is hepatic resec-
.\r., .... r-. 
,\1,;'. f. /<:.11' 
tion ThiS study has dCDmomtrat~d a R-p~ar sunl\al 
rate- of P:y~oI which should be CDlmpar~d with the-
nume-rous studl~s of th~ natural history of he-p,,:i( 
m~taqasCDs for colore-etal canr~r that comistc-nth show 
fe-w or no patients sun'i\'ing bqond :\ ye-ars Of 16S0 
patients with untreated colorectal metaqases to the 
IiH'T reponed in the literature (Table II F~K ", th('rC' ar~ 
onh four who sunived beyond::' years with histologi-
cally documented metastas~s and an additional s('\en 
who survived beyond 5 years without biopsy proof of 
hepatic metastases. These 5-year survivors all ulti-
mately died of hepatic metastases, and no chemothera-
peutic regimen has improved this situation. 
We can limit this literature review to dis~ase that 
was potentially excisable by exrluding what appear to 
be "unexcisable" metastases, such as "primary tumor 
left in plact'," "multiple liver metastases," and "wide-
spread liver metastases," (Table III). This reduces the 
number of evaluable cases but does not remove any 
,-year survivors. There are 11 5-year survivors here. 
but seven did not have hepatic metastases proved at 
biopsy and may not have had liver metastases at all. 
(Bengmark and eafstrom~D found a 5% to 8% rate of 
false-positive diagnoses of liver metastases by surgical 
palpation when biopsy was not performed.) We find, 
restrospectively, that there is a 1 % to 2"10 ,-year 
sun'ival rate in this collected series. When we include 
three case reports from the literature of long-term 
sun'ival with biopsy-proved liver metastases'·': .' (all 
three with widespread and unexcisable metastases). we 
still have only 14 5-year survivors in the English-
language literature, and all died eventually of cancer. 
Com part' this with the 88 ,-year survivors after hepatic 
reseCtion reported here, 58 of whom remain fret' of 
disease to the present time. 
In interpreting our rt'sults in terms of recommenda-
tions for which patients should undergo hepatic resec-
tions, we are implicitly employing a historical control 
group. It has been documented that patients with onlv 
a few metastases confined to the liver have a favorable 
natural history compared wtih all patients with hepatic 
metastases.}l }Q 4{. and no on~ doubts that patients ..... ho 
undergo hepatic resections are a selected subs~tK !'Oe\er-
theless, the available published lit~rature suggests that 
the ,-year sun'ival rat~ even for this subset. if 
untreatt'd, does not exceed ,lfo 10 10'70 (Tables II and 
III). Hence we belie\e that the survival rates reponed 
here indicate that hepatic resection has in fact r~sult~ 
in patient benefit. 
Despite the lack of efficacy of any other treatment, 
physicians continue 10 avoid hepatic resection. When it 
is considered that in the United States approximateh 
1',,/ /, "" 1('; 
10,000 pJ'lmt. ~arh year ar(, candldate-~ for he-patic 
rcsC(!Jon and th:l1 onh approxlm.11ch I,O{l(1 patients 
per Har anualh' undrrgo re~cCliEFnI it f~ obyiou~ that 
thl~ pr(>(rdurc IS shunnt'd by thr maJorm of ph\si-
cians 
In r\aluil1Jng the d~mahilityI of rest'ction for an 
indi\ldual patit'nt, one must take into ac(()unt the risk 
of operative mortality, thr likelihood that the patient's 
disease will be found removablr and the likelihood that 
the patient will be in a prognostic subset for which a 
meaningful 5-year survival rate after resection is 
obtainable It is generally reported that SO'7o or fewer 
patients operated on are found to be eligible for 
resection.:' Increased ability to predict successful 
resection preoperatively awaits improved diagnostic 
methods Even if the surgical mortality ratr were 10%, 
a s-p'ar survival rate of O~lfo to 30"'0 after hepatic 
reseC'tion still represents a rate of 22':0 to 27'70 when 
corrrned for surgical mortality. Such rates make 
hepatic resection appear to be a worthwhile procedure, 
especiallY when we consider that operative mortality 
rates of much less than 10lfo are common in major 
centers ~everthelessI it was our belief that the risk! 
benefit ratio could be improved if we could identify 
subsets of patients who did poorly aftrr hepatic resec-
tion, as such patients could be spared the procedure. 
\\'e also would like to reemphasize that this series 
represents prognostic factors in those patients SUT"<'l1'lng 
the resection. It is not the purpose of this article to 
discuss the morbidity and mortality of he-patic resec-
tion, as this has been addressed in several previous 
articles.}.· The individual surgeon must determine not 
only whether his patient falls into a good prognostic 
group after resection but also whether his patient can 
come through the procedure with an acceptable risk of 
morbidity and mortality. For example. though patients 
olde-r than 70 years appear to have a good prognosis, 
not all patients more than 70 years old can withstand 
this major procedure. 
We hoped that the results of thIS multi-institution 
r('Vle-w would help elucidate the indications and contra-
indications for hepatic resection. Thr numerous series 
that have appeared in the literat ure over the past 10 
years have been relatively- inconsistent in their conclu-
sions because of the inability of any single institution to 
accumulate a large enough sefles of patients to answer 
questions definitivelyK~·~D Though this is a retrospective 
collection of data that includes patients treated by many 
different surgeons at 24 separate institutions, all 
patients are similar in that they ha\'e undergone 
curative excision of all gross disease We believe that 
this analysis has been successful. but even this large 
serie-s leave~ some questions unanswered First, even a 
serir~ a~ lar~r as thiS is n(lt sufllClt'nt to allow us to look 
adequJtrh at comhinations of facton or e'en some 
low-freque-nn subsets of a sim:ir factor. Second. in 
re-trospnti\e mulll-instituticlD studit's that cover a long 
period of time suhstantial amounts of data on factors of 
interest are missing Third, the patients who have 
undergone hepatic resection constitute a selected sam-
ple and thr selection factors probably differ across 
institutions and years. This last point must be borne in 
mind as a caveat for interpretation of the prognostic 
evaluations. For example, the bilobar patients who 
underwe-nt rese-ction are not a random sample of 
"resectable-" bilobar patients, but they may have been 
selected on the basis of factors that are not all identifi-
able-. and the-se patients could have a betler prognosis 
than those selected for resection in the future. 
We have identified a number of factors that influ-
ence prognosis after hepatic resection. The only factors 
that might be considered by themselves as eontraindica-
tions to rese-ction are the presence of positive hepatic 
nodes, the presence of extrahepatic metastases (even if 
removable), or the presence of four or more metastases. 
~fany other factors did act, however, as prognostic 
indicators and should be considered in combination in 
evaluation of the possible benefits of resection. 
Those factors that have some effect on prognosis 
include- the pathologic margin of the liver specimen. 
Patients with a greater than I em margin had a 4p~M 
S-year survjval, whereas patients with a margin of 1 
em or less had a 23% 5-year survival. Data on margin 
width were unavailable for most of our cases, Hence we 
could not include this factor in our multivariate analy-
sis Margin should be taken into account as a stratifi-
cation faclOr for a prospecti\'e re\'iew, and our analysis 
would suggest that a 1 em margin be obtained whenev-
er a liver resection is performed At this time, however, 
this margin d~s not act as a contraindication to 
resection. even if a 1 em margin cannot be obtained. 
There are not enough patients with a lesser margin for 
us to adequately estimate their 5-year sun'i\,al rate. but 
there are ~-year sur\'ivors with such margins. 
The stage of the primary tumor d~s have a strong 
effect on sun'ival. Patients with stage B primary 
tumors do much better than patients with stage C 
primary cancer. Although the patients with a Dukes' C 
primary tumor do have a reasonable 5-year sun'ival 
overall, our multivariate analysis suggests that those 
with multiple metastases and synchronous disease are 
not good candidates for resection Further follow-up 
will help clarify this. 
The disease-free interval d~s act as a prognostic 
j 
, 
indicator. matient~ with a longn dISC'3sC'-frrr InU'rval 
have an impnwrd sunl\al whC'n comparrd ..... ith 
patiCDnt~ with a bnd di~easr-frre intenal The prr,ence 
of synchronoU' mrtastases is not in itself sufflcirot to 
('Xclude patient< from hepatic resrnion. but thi~ must 
be romldered in ronjunction with othrr fa(!ors 
The sIze of a solItary metastasis d~s seem \() affect 
surviva\. in that patients with yen large metastases 
(greater than 8 em) will fare worse than patients with 
small metastases. The number of patients with very 
large metastases is not adequate to enable us to 
precisely estimate their 5-year survival rate; ho ..... ever, 
the actuarial estimate at this time is O~% Hence it does 
not seem appropriate to employ this factor in itself to 
deny patients hepatic resertion Reanalysis with fur-
ther follow-up may provide additional guidelines in the 
f ut ure. 
CEA does appear to affect long-term survival but the 
manner of patients is small, and we would be cautious 
suggesting that low CEAs will lead to a better long-
term survival. 
The type of resection that should be JXrformed has 
been debated in the past. The consensus has been that it 
is unimportant ..... hether a wedge resection or a lobecto-
my is performed. The data from this registry are in 
general agreement with that conclusion. It ..... ould 
appear that patients who undergo a wedge resection 
will fare the same as patients who undergo a lobectomy 
..... hen only small solitary metastases are considered. 
However, patients with large solitary metastases 
(greater than 4 cm) do seem have a worse prognosis 
when undergoing a wedge resection. Patients undergo-
ing anatomic resections, however, have more favorable 
prognoses with respect to stage of disease and free 
interval. We attempted to adjust for this imbalance and 
still found that those patients undergoing wedge resec-
tion appeared to do worse. We think that this is due to 
an inadequate margin on the metastases, since it is 
difficult to do a large wedge resection without coming 
close to the tumor at some point during the dissection. 
\"hen we consider our eXJXrience that anatomic resec-
tions are often less complicated and cause less blood loss 
than large wedge resections. we recommend that 
patients with large metastases (greater than 4 cm) 
undergo anatomic resection, even though this nonran-
domized evaluation cannot be definitive. In addition to 
gi\ing an improved pathologic margin, this also will 
most likely decrease complications and blood loss. 
Our analysis pro\ided no evidence that the presence 
of bilobar disease is a prognostic factor. There were 
only 79 such patients. however, and their long-term 
survival and disease-free survival cannot be estimated 
St,'C o • 
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without furthrr follow-up. At this time, howner. wr 
srr no rrason to takr bilobar disrasr is a contraindica-
tion to resertion 
Patirnts with Pnrtastatic disra~e in hrpatic or crliac 
nodes havr a significantly decrrasrd sunival drspite 
node dissrction. Wr thInk that these patients should not 
undergo hepatic resection. rxcept a~ part of a trial with 
adjuvant therapy. since resection alone is not adequate 
treatment. 
Patients with extrahrpatic metastases resectrd 
simultaneously with liver metastases do appear to have 
survivals similar to those of patients who do not 
undergo extrahepatic resection, although with only 37 
such patients we cannot say this conclusively. The 
diseasr-free survival of these patients is decreased. 
however. From the results of this review, we would 
recommend that patients who have simultaneous extra-
hepatic disease that is removable should undergo both 
liver resection and removal of the extrahepatic disease 
as part of a prospective trial of adjuvant therapy. 
The number of metastases excised was also found to 
be an important prognostic factor. In this series, 
patients with three or more metastases did worse than 
patients with one or two metastases. The multivariate 
analysis suggested that prognosis decreases continuous-
ly as the number of metastases increases from one to 
five. That analysis suggests that stage C patients with 
multiple synchronous metastases are not good candi-
dates for resection but that stage B patients with one to 
three metastases are. The precision of these predictions 
is limited by the small number of patients with 
multiple metastases and the amount of follow-up. We 
recommend that patients with three or more metastases 
should undergo resection only as part of a clinical trial 
and that for patients with two to three metastases the 
decision should take into consideration other factors, 
such as stage. disease-free inten'al, size, margin, and 
age. The effect of number of metastases should be 
reexamined in the future, with further follow-up of 
these patients. 
Many of our patients underwent chemotherapy 
before and after hepatic resection. Agents included 
5-fluorouracil, FCDR, methotrexate, and mitomycin 
C. Routes of administration included hepatic artery. 
portal vein. systemic vein, and intraJXritoneal In this 
retrospective review the variability between route of 
administration and drugs used was too great to permit 
us to come to a firm conclusion as to whether chemo-
therapy improved prognosis It is beyond the capability 
of this analysis to confirm or deny the value of 
chemotherapy combined with hepatic resection; howev-
er, this question has been addressed by several of the 
j'plum. 103 
Sumhr-. 3 
ro-authors of this article in singl~-institutlln series 
Fortner et al.: tried both intra-arterial and IntrafXlnal 
chemotherapy after resection, but in the absence of a 
concurrent control group no definite roncJusion can be 
drawn regarding its efficacy August et al < found a 
suggestion of lessened survival ..... ith use of intrapc-rito-
neal S-Auorouracil after resection, and this is currently 
undergoing a randomized trial at the :\ational Cancer 
Institute O'Connell et al. ... administered intravenous 
5-Auorouracil and semustine after hepatic resection 
and found no improved survival compared ..... ith a 
historical control. Currently there is no evidence that 
chemotherapy after hepatic resection ..... ill improve 
survival; patients should receive chemotherapy only as 
part of a randomized trial. 
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